Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-20-013029
Date:2020-02-24
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
Original Submission Date:

Reporting Person:

LEIDEN JEFFREY M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE BOSTON, MA 02210

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-02-24 F 8,410 d $239.23 103,131 direct
COMMON STOCK 2020-02-25 S 2,273 d $229.77 100,858 direct
COMMON STOCK 2020-02-25 S 1,120 d $230.40 99,738 direct
COMMON STOCK 2020-02-25 S 1,050 d $231.76 98,688 direct
COMMON STOCK 2020-02-25 S 1,017 d $232.96 97,671 direct
COMMON STOCK 2020-02-25 S 1,640 d $234.49 96,031 direct
COMMON STOCK 2020-02-25 S 1,210 d $235.53 94,821 direct
COMMON STOCK 2020-02-25 S 560 d $236.63 94,261 direct
COMMON STOCK 2020-02-25 S 1,680 d $238.33 92,581 direct
COMMON STOCK 2020-02-24 0 $0.00 440 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 transaction made pursuant to dr. leiden's company approved trading plan under rule 10b5-1.
f2 dr. leiden undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
f3 open market sales reported on this line occurred at a weighted average price of $229.77 (range $229.07 to $230.00).
f4 open market sales reported on this line occurred at a weighted average price of $230.40 (range $230.14 to $230.73).
f5 open market sales reported on this line occurred at a weighted average price of $231.76 (range $231.27 to $232.14).
f6 open market sales reported on this line occurred at a weighted average price of $232.96 (range $232.27 to $233.11).
f7 open market sales reported on this line occurred at a weighted average price of $234.49 (range $233.99 to $234.66).
f8 open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.07 to $235.72).
f9 open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.56).
WhaleWisdom Logo

Elevate your investments